Medical Therapy for Pediatric Inflammatory Bowel Disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Pediatric inflammatory bowel disease encompasses a spectrum of disease phenotype, severity, and responsiveness to treatment. Intestinal healing rather than merely symptom control is an especially important therapeutic goal in young patients, given the potential for growth impairment as a direct effect of persistent chronic inflammation and the long life ahead, during which other disease complications may occur. Corticosteroids achieve rapid symptom control, but alternate steroid-sparing strategies with greater potential to heal the intestine must be rapidly adopted. Exclusive enteral nutrition is an alternate short-term treatment in pediatric Crohn’s disease. The results of multi-center pediatric clinical trials of both infliximab and adalimumab in Crohn’s disease and of infliximab in ulcerative colitis (all in children with unsatisfactory responses to other therapies) have now been reported and guide treatment regimens in clinical practice. Optimal patient selection and timing of anti-TNF therapy requires clinical judgment. Attention must be paid to sustaining responsiveness safely.
- Benchimol E, Fortinsky K, van der Heuvel M, van Limbergen J, Griffiths AM. Epidemiology of pediatric IBD: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–39. CrossRef
- Braegger C, Balabbeni P, Rogler D, et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at an earlier age? J Pediatr Gastro Nutr. 2011;53:141–4. CrossRef
- Imielinski M, Baldassano R, Griffiths AM, et al. Common variants at 16p11 implicate IL-27 in childhood-onset inflammatory bowel disease. Nat Genet. 2009;41:1335–40. CrossRef
- •• Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45. A landmark paper which breaks new ground in infantile-onset multi-system inflammatory disorders that include intestinal inflammation and even perianal disease, but also stimulates research into the role of the IL-10 pathway in complex IBD. CrossRef
- • Levine A, Griffiths AM, Markowitz J, et al. Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease - the Paris Classification. Infl Bowel Dis Inflamm Bowel Dis. 2011;17:1314–21. A critical attempt to define important phenotypic characteristics of pediatric onset IBD. CrossRef
- •• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114–22. A careful prospective analysis of the clinical evolution of pediatric IBD in comparison to adult onset IBD diagnosed in Scotland. CrossRef
- •• Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106–13. Appearing at the same time, an examination of the phenotypic evolution of pediatric IBD in a population-based French cohort. CrossRef
- • Walters TD, Griffiths AM. Mechanisms of Disease: growth impairment in paediatric Crohn’s disease. Nature Rev Gastroenterol Hepatol. 2009;6:513–23. A comprehensive review of pathogenetic mechanisms of growth impairment in pediatric CD. CrossRef
- • Wilson D, Thomas A, Croft N, et al. Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2010 Jan 13. A comprehensive magnum opus, which recognizes the paucity of randomized controlled trials in children.
- Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18(3):509–23. CrossRef
- Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008 Jul 16;(3)(3):CD000296.
- Levine A. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn’s disease: A randomized placebo-controlled trial. Inflamm Bowel Dis. 2009;15:1055–61. CrossRef
- Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30(5):501–7. CrossRef
- Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744–53. CrossRef
- Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2008;27(4):293–307. CrossRef
- • Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008;28(6):724–33. An interesting attempt to investigate the mechanism of action of enteral nutrition as primary therapy. CrossRef
- Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–73. CrossRef
- • Hyams J, Griffiths AM, Markowitz J et al Induction and Maintenance Adalimumab for Moderate to Severe Crohn’s Disease in Children: A Randomized Double-Blind Trial. Gastroenterology 2011;140:S90. A large multi-center trial by pediatric standards, with nice stratification of patients according to prior anti-TNF exposure.
- Hanauer SB, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359:1451–9. CrossRef
- Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38. CrossRef
- Borelli O, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis. 2004;36:342–7. CrossRef
- Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38.
- D’Haens G, et al. Early combined immunesuppression or conventional management in recently diagnosed patients with Crohn’s disease: an open randomized trial. Lancet. 2008;371:660–7. CrossRef
- Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–9. CrossRef
- Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119(4):895–902. CrossRef
- Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102(12):2804–12. CrossRef
- Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm Bowel Dis. 2006;12(11):1053–7. CrossRef
- Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–54. CrossRef
- •• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. Conducted in adult patients, but addressing what has been a major question about optimal treatment regimens with infliximab therapy (mono- versus combination). Also provides prospective data on mucosal healing rates with azathioprine and with infliximab and with combination therapy. CrossRef
- • Schnitzler F, et al. Longterm outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–8. Excellent single-center account of real-world experience in adults. Similar is needed in pediatrics!. CrossRef
- deRidder L, et al. Infliximab Dependency in Pediatric Crohn’s Disease: Longterm follow-up of an Unselected Cohort. Inflamm Bowel Dis. 2008;14:353–8. CrossRef
- • Shale M, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639–41. Excellent summary and analysis. CrossRef
- Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale. Inflamm Bowel Dis. 2007;13(8):1024–30. CrossRef
- • Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1. Another up to date summary and analysis. CrossRef
- Melmud G, et al. The appropriateness of concomitant immunemodulators with anti-TNF agents for Crohn’s disease: one size does not fit all. Clin Gastro Hepatol. 2010;8:655. CrossRef
- Maini RN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63. CrossRef
- Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease. Inflamm Bowel Dis. 2007;13:1–7. CrossRef
- Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):946–53. CrossRef
- Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–32. CrossRef
- Zeisler B, Lerer T, Markowitz J et al. Outcome following aminosalicylate therapy in children newly diagnosed with ulcerative colitis: a prospective multi-center registry experience.
- Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastro Hepatol. 2006;4(9):1118–23. CrossRef
- Hyams J, Damaraju L, Blank M et al. A randomized multi-center open label phase 3 study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate to severe ulcerative colitis. Clin Gastro Hepatol 2011. doi:10.1016/j.cgh.2011.11.026.
- Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437–43. CrossRef
- Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;5:981–7. CrossRef
- Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut. 2008;57:1–10. CrossRef
- Turner D, Griffiths A. Acute severe paediatric ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2011;17:440–9. CrossRef
- • Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282–91. The first sizeable prospective assessment of intravenous corticosteroid therapy for acute severe pediatric ulcerative colitis. CrossRef
- • Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastro. 2011;106:574–88. A useful guide to management of this severe cohort of patients. CrossRef
- Medical Therapy for Pediatric Inflammatory Bowel Disease
Current Gastroenterology Reports
Volume 14, Issue 2 , pp 166-173
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Pediatric inflammatory bowel disease
- Inflammatory bowel disease
- Crohn’s disease
- Ulcerative colitis
- Enteral nutrition
- Industry Sectors